Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2016 / Aug / Visual acuity outcomes at one year in a national multicentre audit of aflibercept for treatment-naïve neovascular AMD
Retina Sponsored

Visual acuity outcomes at one year in a national multicentre audit of aflibercept for treatment-naïve neovascular AMD

Sponsored By Bayer 8/9/2016 1 min read

Share

Therapeutic strategies using intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy have advanced the standard of care for neovascular agerelated macular degeneration (nAMD), preventing moderate visual acuity (VA) loss in most patients with nAMD. However, for optimal treatment outcomes, continuous or frequent injections and/or regular monitoring are required.

The greatest vision outcomes observed in clinical trials evaluating antiangiogenic agents ranibizumab and unlicensed bevacizumab for nAMD have been obtained with a 4-weekly dosing regimen (1–3). In the VIEW 1 and VIEW 2 (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) studies, two similarly designed, phase 3 randomised controlled clinical trials, aflibercept dosed either monthly or given bimonthly after 3 monthly loading injections was non-inferior to monthly ranibizumab in maintaining vision (losing <15 Early Treatment Diabetic Retinopathy Study [ETDRS] letters), and provided significant VA gains (≥15 letters vs. baseline VA) comparable to monthly ranibizumab at 52 weeks (4).*

Clinical trial treatment regimens for nAMD present challenges in real-world practice
Improvements in mean visual acuity observed in randomised clinical trials of anti-VEGF therapy for nAMD have not always been consistently replicated in everyday clinical practice (5–10). Patient heterogeneity, measurement techniques, the quality of service delivery, treatment regimens, and adherence with recommended protocols differ substantially in clinical settings within and across national health systems. Delays in the initiation of treatment, as well as recurrence of neovascular activity and/or progressive morphological changes, may lead to visual acuity loss (10,11). Discontinuous or variable follow-up in routine clinical care may also underlie observations of reduced efficacy of anti-VEGF therapy compared with clinical trial results (5–10). Service capacity and resource constraints pose challenges adopting and following the treatment regimens associated with optimal vision gains for patients with nAMD, with a continuous retreatment and monitoring burden impacting healthcare providers, patients, and national health systems. Various proactive and reactive anti-VEGF treatment regimens for nAMD have been progressively adopted in retinal practice in an effort to decrease injection and monitoring frequency. These include fixed-interval, pro re nata (PRN, treatment as needed), treat to target, and treat-and-extend protocols, as well as combination approaches.

Download the pdf here

This supplement was funded by Bayer. Bayer checked the content for factual accuracy to ensure it is fair and balanced, and that it complies with the ABPI Code of Practice. The views and opinions of the author are not necessarily those of Bayer or the publisher. No part of this publication may be reproduced in any form without the permission of the publisher. Prescribing information can be found on the back cover of the PDF download.

About the Author(s)

James Talks

James Talks is a Consultant Ophthalmologist at the Royal Victoria Infirmary, Newcastle upon Tyne, UK

More Articles by James Talks

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: